Abstract: Obesity and excess of adipose tissue are associated with the development of cardiovascular risk factors such as diabetes, hypertension, and hyperlipidemia. At the cardiac level, various morphological adaptations in cardiac structure and function occur in obese individuals. Different mechanisms linking obesity to these modifications have been postulated. Adipose tissue and epicardial fat releases a large number of cytokines and bioactive mediators such as leptin. Leptin circulates in proportion to body fat mass, thus serving as a satiety signal and informing central metabolic control centers as to the status of peripheral energy stores. It participates in numerous other functions both peripherally and centrally, as indicated by the wide distribution of leptin and the different isoforms of its receptor in different tissues including the heart. This hormone has distinct effects on the reproductive, cardiovascular, and immune systems; however, its role in the heart could mediate wide physiological effects observed in obese individuals. Oxidative stress is associated with obesity and may be considered to be a unifying mechanism in the development of obesity-related comorbidities. It has been reported that obesity may induce systemic oxidative stress; in turn, oxidative stress is associated with an irregular production of adipokines. We herein review the current knowledge of cardiac effects of leptin and the possible mechanisms that are involved, including oxidative stress that plays a major role in the development of cardiovascular damage.
Introduction
Obesity is an important risk factor for the development of vascular and cardiac alterations and is consequently associated with an increased cardiovascular morbidity and mortality. In recent years, the incidence of obesity has been increasing in society, and it is currently a major health problem. Obesity is an exaggeration of normal adiposity and is a central player in the pathophysiology of various diseases such as type 2 diabetes mellitus, cardiovascular disease, stroke, hypertension, and hyperlipidemia, largely explained by the excessive accumulation of adipose tissue. Obesity is characterized by the increase in adipocyte size and number, which determine changes in the pattern of the production of adipokines. Therefore, targeting adipose tissue has become a new strategy for obesity treatment and includes suppression of adipogenesis or adipose tissue mass, obstruction of lipid accumulation in adipocytes, and adipocyte deletion by apoptosis [1, 2] .
Although it is widely accepted that obesity increases the risk of developing heart disease, an obesity paradox exists since a growing number of recent reports document a statistically significant survival benefit in obese patients once they have been diagnosed with cardiovascular diseases [3] [4] [5] .
Obesity-related inflammatory, metabolic, and hormonal changes have been postulated to contribute to the development of the cardiac complications of obesity that can eventually trigger the development of heart failure. The role of adipose tissue with its secretory products (adipokines) as an active endocrine organ is gaining importance in the investigation of obesity-associated diseases through the activation of proinflammatory state as well the increase of some adipokines that can affect the cardiovascular system. One of these adipokines that has been postulated as a link between obesity and cardiovascular damage is leptin.
This review describes the cardiac effects of leptin and possible mechanisms that are involved, including oxidative stress that plays a major role in the development of cardiovascular damage.
Leptin
The discovery of leptin in 1994 [6] has allowed a tremendous advance in the neurobiology of energy homeostasis and obesity. Leptin, the product of the ob gene, is a 16-kDa peptide hormone that circulates in proportion to body fat. The ob gene is located on chromosome number 7 in humans and number 6 in mice. This hormone is considered to be a critical signal that provides feedback to inform the central nervous system about the status of peripheral energy reserves [7] . Although circulating levels of leptin rise in obesity, these individuals are thought to be leptin resistant due to the lack of satiation observed [8] . However, there is a growing awareness of selective leptin resistance that manifests itself as an absence of leptin's central satiety functions, which does not occur concurrently with its peripheral effects or other centrally mediated effects, including sympathetic nerve activity [9, 10] . It is now appreciated that this hormone has many additional effects, often as a consequence of direct peripheral actions. These include angiogenesis, hematopoiesis, lipid and carbohydrate metabolism, and effects on the reproductive, cardiovascular, and immune systems. Thus, changes in plasma leptin concentrations can have important and wide-ranging physiological implications.
Adipocytes are the major source of leptin synthesis and secretion; other sources include placenta, stomach, and heart [11] [12] [13] [14] . Leptin expression can be induced by obesity, insulin, tumor necrosis factor-α (TNF-α), and glucocorticoids and is negatively regulated by fasting, β-adrenergic agonists, and thiazolidinediones [15] . Leptin acts via transmembrane receptors (obR), which show structural similarity to those of the cytokine family [15] .
Leptin receptors
Leptin receptors are the product of db gene, first identified by expression cloning techniques. The gene is alternatively spliced to produce at least six isoforms (obRa-obRf). Although the extracellular domain is conserved across all isoforms of the receptor, the length of the intracellular domains varies [7] . The isoform obRe is different because it is the only one that neither possesses a transmembrane domain nor plays a direct role in leptin signaling but is likely important in determining the amount of leptin in circulation. Other isoforms possess a transmembrane domain that is composed of 23 amino acids. The isoforms obRa, obRc, obRd, and obRf possess short intracellular domains with 32 to 40 amino acids, while the isoform obRb has a long intracellular domain with approximately 306 amino acids and appears to mediate most of the biological effects of leptin [16] . The intracellular domain of all isoforms contains an identical 29-amino-acid sequence containing a "Box 1" Janus family tyrosine kinase (JAK) binding domain, while obRb also contains a "Box 2" motif and signal transducers and activators of transcription (STAT) binding sites [15] . Leptin receptors are present in many peripheral tissues, including those of the cardiovascular system.
Cardiac effects of leptin
The discovery of leptin production by the heart [17] has strengthened the suggestion that leptin can directly mediate cardiac-specific effects since leptin receptors are also present in the heart, supporting that leptin can serve as a regulator of cardiac function via paracrine and autocrine mechanisms. This role could be relevant in certain situations in which leptin levels are increased, such as obesity.
Abundant evidence shows that obesity is associated with structural and functional changes in the heart characterized by left ventricular (LV) hypertrophy, left atrial enlargement, and impairment of LV systolic and diastolic functions, which are believed to be precursors to more overt forms of cardiac dysfunction and heart failure.
There are different mechanisms that can contribute to these structural and functional alterations in the heart in obesity such as metabolic changes, cardiomyocyte hypertrophy, changes in extracellular matrix (ECM) turnover, apoptosis, and oxidative stress. As has been suggested, leptin could potentially participate in all of these.
Metabolic effects
Obesity is associated with changes in cardiac metabolism characterized by reduced myocardial glucose utilization, which could involve changes at transport, glycolysis, and oxidation levels. This reduced glucose utilization is accompanied by increased myocardial fatty acid (FA) utilization, and myocardial oxygen consumption (MVO 2 ). These changes could generate accumulation of intracellular lipids, contributing to the increased prevalence of cardiomyopathies in the obese population [18] . These changes seem to be the earliest measurable abnormality in the heart, as has been suggested in experimental studies, and lead to cardiac function alterations [19] . Several adipokines, such as leptin, adiponectin, and TNF-α, have emerged as potential players in these metabolic alterations via endocrine effects that impact upon cardiac function [20] .
In high-fat-diet (HFD) mice, Wright et al. have found that hearts rapidly adapt to caloric excess, which is associated with mildly abnormal glucose tolerance. MVO 2 and FA oxidation are increased at only 2 weeks from the beginning of intake, whereas rates of glucose oxidation and glycolysis are reduced. These metabolic changes were associated with impaired GLUT4 translocation to the membrane but normal pyruvate dehydrogenase activity and malonyl CoA concentrations, indicating changes in glucose transport but not in its metabolism pathways. In addition, these alterations occur without changes in mitochondrial uncoupling. These results indicate that impaired glucose utilization might be the initial defect that precipitates altered myocardial substrate utilization following short-term high-fat feeding [21] .
In young Zucker diabetic fatty (ZDF) rats (11 weeks old), Chatham and Seymour have seen significant alterations in oxidative and nonoxidative cardiac carbohydrate metabolism in the absence of overt changes in systolic function. This model of rat developed hyperglycemia after 6 weeks of age, so these results confirm that, shortly after the development of diabetes, there are alterations in cardiac carbohydrate metabolism preceding the onset of contractile dysfunction, supporting the hypothesis that alterations in the regulation of energy metabolism could contribute to the development of cardiomyopathy diabetic in obese animals [22] . The last decade has seen intense research interest in the role of adipokines as regulators of metabolic homeostasis. In order to explore the effects of the extensive crosstalk between signaling pathways regulated by various adipokines, which exists in vivo, Palanivel et al. investigated the influence of adipokines derived from primary adipocytes in glucose and FA uptake and metabolism in isolated primary cardiomyocytes. Either coculture of these cell types or incubation with adipocyte-conditioned medium significantly increased glucose uptake in cardiomyocytes. When streptozotocininduced diabetic rats were used as a source of adipocytes, there was a lower ability to elicit glucose uptake in cardiomyocytes, which corresponded with lower Akt and AMPK phosphorylation. Examination of FA uptake revealed that stimulation only occurred in response to adipokines secreted by wild-type rat adipocytes. Importantly, oxidation of FA by cardiomyocytes was decreased by adipokines derived from diabetic rat adipocytes. Analysis of adipokine profiles in diabetic rat adipocyte-conditioned medium demonstrated the most significant increase in leptin/adiponectin ratio mainly due to a decrease in adiponectin levels as well as increased interleukin (IL)-6 expression. Taken together, these data suggest that the profile of adipokines secreted by adipocytes from diabetic rats has a deleterious influence on cardiomyocyte metabolism [20] . However, this study does not explain the direct effect of each adipokine.
Different reports have demonstrated direct metabolic effects of leptin on cardiomyocyte metabolism via treating cells with individual recombinant forms of this adipokine [23] [24] [25] . FA oxidation is triggered by the activation of cardiac AMPK, which reduces acetyl-CoA carboxylase (ACC) activity. Leptin alters cardiac metabolism in isolated treated hearts from rats by increasing FA oxidation independently of AMPK. Leptin has no effect on cardiac AMPK activity or AMPK phosphorylation and produces no changes in ACC activity or malonyl-CoA levels [26] . These results suggest that other signaling pathways and targets are involved. Nitric oxide and p38 mitogen-activated protein kinase (MAPK) activation are known to stimulate glucose uptake and glycolysis [27] . In this regard, it has been demonstrated in isolated hearts that leptin stimulates nitric oxide through activation of the JAK/STAT pathway. An increase in nitric oxide production in turn stimulates p38 MAPK, producing parallel stimulation of FA oxidation and inhibition of cardiac function, but independent of any effect on FA-dependent mitochondrial respiration or uncoupling activity. Therefore, leptin seems to stimulate FA oxidation by a STAT3/nitric oxide/p38 MAPK-dependent mechanism through a pathway that is upstream of mitochondria [28] .
In HL-1 cells, a mouse atrial cardiomyocyte line, leptin quickly increased FA uptake and oxidation; however, oxidation decreased over time, leading to intracellular lipid accumulation, which may lead to lipotoxic consequences that can trigger apoptosis and potentially facilitate the development of heart failure. Leptin did not alter basal or insulin-stimulated glucose uptake or metabolism as was expected [29] . It is important to consider that in vitro and in vivo observations may differ for a variety of reasons, including contribution from central nervous system modulation [30] .
Besides these reported deleterious effects of leptin on cardiac metabolism, a protector effect has been suggested. At 4 weeks of age, hearts of obese animals with impaired leptin signaling (ob/ob and db/db mice), which develop diabetes at a very young age, exhibit decreased glucose oxidation rates and increased rates of FA oxidation and MVO 2 . All these changes are accompanied by decreased cardiac performance. These alterations are associated with myosin isoform switching, which precede the onset of hyperglycemia. All of these changes were in the absence of modifications of peroxisome proliferator-activated receptor (PPAR)-α in 4-week-old animals. Increased PPAR-α signaling has been suggested to be an important underlying mechanism that may be responsible for the metabolic changes in the diabetic heart, mediating its effects by increasing the expression of enzymes involved in FA mitochondrial β-oxidation and increasing the expression of uncoupling proteins (UCPs), which may increase mitochondrial FA flux. Although the results seem to be independent of PPAR-α signaling, it is likely that PPAR-α signaling will exacerbate these metabolic disturbances after the onset of hyperglycemia [19] . In agreement with this protective role of leptin, other results have shown that leptin is able to increase glucose uptake and oxidation [31] .
In conclusion, the specific metabolic effects of leptin are not well established, so it is necessary to continue with experiments to elucidate these controversial opinions.
Hypertrophic effects
Obesity is associated with cardiac remodeling in which structural changes such as hypertrophy are present. Although hypertrophy can be a beneficial adaptive response to myocardial injury, it is generally perceived that progressive myocardial hypertrophy contributes to remodeling and development of heart failure [32, 33] .
Different data have demonstrated that leptin can induce cardiac hypertrophy through different mechanisms. Continuous infusion of leptin for 4 weeks following myocardial infarction mice has demonstrated an increase in both LV chamber diameter in end diastole and fractional shortening when compared with control group (without leptin infusion). Thus, chronic leptin infusion resulted in eccentric dilatation with augmented systolic function [34] .
In rat neonatal cardiomyocytes, leptin for 24 h increased cell surface area and expression of α-skeletal actin, a fetal gene, and MLC-2, a constitutive gene, which are up-regulated in cardiac hypertrophy. MAPK is an important mediator of cardiac hypertrophy [35] . When cells were exposed to leptin in the presence of MAPK inhibitors, the hypertrophic effect of leptin was completely abrogated, indicating activation of MAPK signaling in this process [33] . Similarly, leptin induces the elongation of primary cardiac myocytes via a JAK/STAT pathway, indicating that different pathways could be involved in hypertrophic action of leptin [28] .
It has been well documented that reactive oxygen species (ROS) play an important role in the development of cardiac hypertrophy [36, 37] . Studies have shown that endothelin-1 (ET-1), whose levels are increased in obese subjects, induces cardiomyocytes hypertrophy by stimulating ROS production. Leptin induces hypertrophy in cultured rat neonatal cardiomyocytes in a dosedependent manner. This effect seems to be mediated through ET-1 production and by the increase of oxidative stress. These effects of leptin were inhibited by pretreatment with ABT-627, a selective ETA receptor antagonist, and catalase, an enzyme that specifically decomposes hydrogen peroxide (H 2 O 2 ) to water and molecular oxygen in the cultured neonatal rat cardiomyocytes. However, the blockade of ETA receptors cannot completely abolish leptin-induced ROS production and hence the hypertrophic effect in the cultured neonatal rat cardiomyocytes. Therefore, we can conclude that the ET-1/ETA pathway is only one of the contributing factors in leptin-induced cardiomyocyte hypertrophy [38] . In this sense, Rajapurohitam et al. have studied the effects of leptin as a mediator of the hypertrophic effects of angiotensin II and ET-1 in cultured rat myocytes. It is well known that cardiac pathologies are associated with up-regulation of the renin-angiotensin and endothelin systems [39, 40] . A similar up-regulation has been found in obesity. Data show that angiotensin II and ET-1 induced hypertrophy in rat cardiomyocytes, which was reversed in the presence of antibodies directed against the leptin receptor. Furthermore, cardiomyocytes treated with angiotensin II or ET-1 manifested an increase in the release of leptin, revealing that hypertrophic response to either angiotensin II or ET-1 was associated with a marked up-regulation of the leptin system [41] .
The Rho family (RhoA, Rac1, and Cdc42) and mammalian target of rapamycin (mTOR) have emerged as important regulators of cell growth [42] [43] [44] . Phosphatidylinositol 3-kinase (PI3K) and Akt are up-regulated in response to pressure overload-induced cardiac hypertrophy; a downstream target of the PI3K/Akt pathway is mTOR. Through the use of inhibitors of different components of these pathways, Zeidan et al. have identified an interaction between JAK2/PI3K/Akt/mTOR and the RhoA and Rac1 signaling pathways in mediating leptin-induced cardiomyocyte hypertrophy associated with GATA4 (transcriptional factor) stimulation, which regulates myocardial differentiation and function [11] .
Although the prohypertrophic effect of leptin is well accepted, one study shows that leptin could contribute to the maintenance of normal cellular structure. Barouch et al. have studied the effects of leptin on cardiac hypertrophy in normotensive ob/ob mice that suffer caloric restriction to induce weight loss. In this study, leptin contributes to the maintenance of normal LV wall thickness and myocyte cellular structure. When they replete leptin to maintain its levels constant, LV hypertrophy reverts to normal in ob/ob mice, but caloric restriction does not, so these results are independent of overall body weight or hemodynamic load. Furthermore, both leptin repletion and caloric restriction reduce myocyte hypertrophy, although leptin does so to a much greater degree, indicating that, at a cellular level, there is an additive effect of these two interventions [45] . However, these results should be interpreted cautiously, because the reversal of hypertrophy in this model may not reflect a direct effect of leptin on the cardiomyocyte but instead a reversal of obesity-related systemic metabolic and other abnormalities seen with chronic leptin deficiency.
Effects on the ECM
Chronic cardiovascular stress or other pathophysiological stimuli induce modifications in the organization and structure of the myocardial ECM. These changes can profoundly alter cardiac size, structure, and function [46, 47] .
Remodeling does not simply involve altered total levels of matrix collagens; the type of collagen and its organization and cross-linking are of great significance [48] . Collagen is the major stress-bearing element within the ECM and forms a three-dimensional network around bundles of myocytes to generate a stress-tolerant network. Hence, the importance of cardiac fibroblasts extends far beyond being simple regulators of ECM production. These cells are critical not only to normal myocardial function but also to the remodeling that occurs in response to pathological changes, such as obesity and hypertension [49] .
Endogenous leptin contributes to ECM remodeling by increasing expression of different compounds such as fibronectin and collagen type I and III in rats subjected to coronary artery ligation (CAL) at 7 days after infarction. The role of leptin to this increment can be seen from the observation that the increase in expression of fibronectin and collagen was abrogated after infusion with a neutralizing leptin receptor [50] .
The turnover of collagen is regulated by the family of matrix metalloproteinases (MMPs). A detrimental consequence of MMP dysregulation is the abnormal accumulation of collagen leading to cardiac fibrosis [51] . A consequence of excessive MMP activity during remodeling is the replacement of the normal highly structure matrix collagen profile by fibrous interstitial deposits of poorly cross-linked collagens [52] . Leptin is able to increase the proteolytic activity of MMP-2 in a dose-and time-dependent manner in neonatal rat cardiac myofibroblasts. This ability of leptin appears to be mediated by the influence of leptin to increase total and cell surface of MT1-MMP, a membrane-bound MMP isoform able to degrade matrix components and activator of MMP-2 [51] . These effects are accompanied by increases in intracellular and secreted procollagen type I levels but not in procollagen type III levels, suggesting that the impact of leptin on collagen synthesis can be different depending on the type or which cell is considered.
Supporting this idea, it has been shown that leptin increases procollagen type III and IV mRNA levels in human ventricular cardiomyocytes but decreases these levels in those of procollagen type I, resulting in no changes in total collagen levels, although changing the overall profile. These results are accompanied by an increment in MMP-2 expression due, at least in part, to the c-Jun NH 2 -terminal kinase (JNK) and MAPK pathways [52] . Same results can be seen in HL-1 cardiomyocytes, but leptin is able to increase collagen synthesis in these cells as well as modulate its degradation, since it decreased the levels of the endogenous MMP inhibitor, TIMP-1, altering the MMP/ TIMP ratio [53] .
Reorganization of the actin cytoskeleton is one mechanism through which MT1-MMP, activator of MMP-2, may move to the cell surface. Remodeling of the actin cytoskeleton can be regulated by a variety of signaling pathways, for example, the small G protein Ras homolog gene family (Rho) and Rho-associated coiled-coil-forming protein kinase (ROCK). Acute and chronic treatment with leptin led to reorganization of the actin cytoskeleton and in particular to increase actin stress fiber formation. Leptin increases MT1-MMP trafficking to the cell surface, increasing extracellular pro-MMP-2 activation and fibroblast migration. These effects are dependent on Rho/ROCK signaling to remodel the actin cytoskeleton and increase F-actin stress fiber formation [46] . Therefore, all the data suggest that leptin exert a profibrotic action on the heart-modifying ECM balance. To date, not too much information about the effects of leptin on cardiac ECM are available, so more studies on the mechanism involved are required and could be of great importance in the physiopathological role of leptin in cardiac remodeling.
Apoptosis
Alterations in cardiac metabolism present in obesity may lead to the accumulation of products such as triacylglycerol, diacylglycerol, and ceramide. This may lead to dysfunction and/or myocyte death [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . Myocyte apoptosis has been suggested to be an important etiological component of heart failure [57] [58] [59] , particularly in the transition from compensatory remodeling to heart failure [60] .
A commonly proposed mechanism for lipid-induced cardiomyocyte death is via the activation of caspases by ceramide, a potent proapoptotic byproduct of lipid metabolism. In rats fed a HFD composed mainly of saturated FAs, ceramide levels and the numbers of apoptotic events are higher than in rats fed with HFD composed of unsaturated FAs, indicating the importance of the composition of FA in the diet. These effects are accompanied by lower serum leptin levels in saturated HFD rather than in unsaturated HFD, indicating the possible antiapoptotic effects of leptin [55] .
Obese animals demonstrate increased cardiac myocyte apoptosis compared with wild-type mice due to alterations in leptin signaling (ob/ob and db/db mice). This increase in apoptosis is associated with more DNA damage and decreased long-term survival. In leptin-deficient (ob/ob) mice, cardiac tissue lipids levels are higher, and leptin repletion reverses this accumulation with abolition of the apoptosis. This is not true in mice with mutation of the leptin receptor (db/db), indicating that leptin plays an important role in cardioprotection [61] .
In the heart, bcl-2 limits apoptosis and protects against cardiac ischemia/reperfusion damage in vivo [62] . What is more, survivin, a protein member of the inhibitor of apoptosis family that inhibits caspase activation, decreases apoptosis in failing myocardium [63] . Both bcl-2 and survivin are induced by the activation of the STAT3 pathway [64, 65] and both have been shown to be up-regulated by leptin through leptin receptor-mediated STAT3 signal transduction. Leptin-deficient ob/ob mice have worse survival and cardiac function relative to wild-type or leptinreplete ob/ob mice after CAL. Leptin deficiency and its accompanying loss of cardiac STAT3 activation are linked to decreased expression of the antiapoptotic genes bcl-2 and survivin in the heart after CAL. These data provide evidence that intact leptin signaling limits cardiac apoptosis, especially in the setting of myocardial injury after CAL [66] . Other studies have shown that leptin treatment in ob/ob mice reverses the increased lethality induced by lipopolysaccharide [67] .
Leptin can protect cardiomyocytes by ROS [36, 68] . Acute treatment of leptin (1 h) exerts a protective effect against H 2 O 2 in H9c2 rat cardiomyocytes by preventing activation of components of the mitochondrial-dependent intrinsic pathway of apoptosis; however, this effect is not observed at 24 h of treatment with leptin. These results could be by lipid accumulation in long treatment leptin [68] .
Serum deprivation, which occurs in ischemia conditions, has been shown to induce apoptosis in cultured cardiomyocytes dependent on oxidative stress. In these conditions, leptin decreases the number of apoptotic cardiomyocytes in a dose-dependent manner, which is associated with enhanced superoxide dismutase (SOD) activity and blunted caspase-3 activation. These data suggest that the antiapoptotic effects of leptin may be consequent to increased antioxidant defense [69] . Despite these results, it is necessary to treat these data with caution since, as we discuss below, several studies have demonstrated that leptin can stimulate the production of ROS.
Oxidative effects
Over the past several decades, clinical and experimental studies have provided substantial evidence that oxidative stress, defined as an excess ROS production relative to antioxidant defense, is enhanced in different pathological conditions, including obesity. Excessive ROS causes protein and lipid peroxidation and DNA damage and can lead to irreversible cell damage, cellular dysfunction, and death, which have been implicated in a wide range of pathological cardiovascular conditions [70] . ROS can activate cell migration and proliferation and appear to control the expression of adhesion molecules and chemotactic factors, which are proinflammatory molecules in endothelial cells. Furthermore, ROS are able to activate transcriptional factors, such as nuclear factor-κB (NF-κB), and can affect intracellular transduction pathways functioning as signal messengers [71] . Specifically, ROS can directly impair contractile function by modifying proteins central to excitation-contraction coupling. Moreover, ROS activate a broad variety of hypertrophy signaling kinases and transcription factors and mediate apoptosis. It also stimulates cardiac fibroblast proliferation and activates the MMPs, leading to the ECM remodeling. These cellular events are involved in the development and progression of maladaptive myocardial remodeling and failure [70] .
The cellular sources of ROS generation within the heart include cardiac myocytes, fibroblasts, endothelial cells, and neutrophils. Within cardiac myocytes, ROS can be produced by several sources, including mitochondria and different enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, and uncoupled nitric oxide synthase (NOS). A large body of evidence supports the concept that ROS are formed within mitochondria under physiological and pathological conditions. The superoxide anion formed by complex I and III in electron chain transport is rapidly transformed into H 2 O 2 by the SOD. When mitochondrial antioxidant defenses are hampered, cardiovascular diseases are exacerbated. The mitochondrial formation of ROS may be modulated by nitric oxide as a consequence of the inhibition of cytochrome oxidase. This reversible process can be transformed into irreversible damage to the respiratory chain when nitric oxide formation is sustained. Indeed, the reaction of nitric oxide with superoxide anion generates peroxynitrite, which can cause the irreversible nitration of proteins [72] . Mitochondria are an important source of ROS in failing hearts, indicating a pathophysiological link between mitochondrial dysfunction and oxidative stress [73] . When oxygen availability is reduced in conditions such as ischemia or hypoxia, mitochondrial formation of ROS is increased, which can contribute to the induction of myocyte damage or myocardial infarction [74] .
ROS can be also generated via NAD(P)H oxidase and/ or xanthine oxidase in different cells. The major source of NADH generation in the cytosolic region appears to be glyceraldehyde-3-phosphate dehydrogenase in glycolysis. NADPH is the major source of superoxide anion in the cardiovascular system. The phagocytic NADPH oxidase consists of two membrane-bound subunits (Nox2 and p22phox) and cytosolic subunits (p47phox, p67phox, p40phox, and rac2). Numerous findings suggest that phagocytic NADPH oxidase is involved in cardiac damage [75] .
It has been reported that obesity may induce systemic oxidative stress; in turn, oxidative stress is associated with an irregular production of adipokines. The sensitivity of C-reactive protein (CRP) and other biomarkers of oxidative damage are higher in individuals with obesity and correlate directly with body mass index (BMI) and the percentage of body fat, low-density lipoprotein (LDL) oxidation, and triglyceride (TG) levels; in contrast, antioxidant defense markers are lower according to the amount of body fat and central obesity. The increase obesity-associated oxidative stress is probably due to the presence of excessive adipose tissue because adipocytes and preadipocytes have been identified as a source of proinflammatory cytokines. These cytokines are potent stimulators for the production of ROS by macrophages and monocytes, and a rise in the concentration of cytokines could therefore be responsible for increased oxidative stress. Furthermore, obesity increases the mechanical load and myocardial metabolism; therefore, oxygen consumption is increased. One negative consequence of increased oxygen consumption is the production of ROS derived from the increase in mitochondrial respiration and, of course, from the loss of electrons produced in the electron transport chain, resulting in the formation of superoxide radical.
Consumption of diets high in fat could change the metabolism and increase myocardial FA utilization and oxygen consumption with fatty deposits being susceptible to suffer oxidation reactions. If the production of these ROS exceeds the antioxidant capacity of the cell, ROS result in lipid peroxidation, which contributes to the development of atherosclerosis [76] .
Some studies show a relationship between obesity and antioxidant defense, decreasing the activity of enzymes such as SOD and catalase [77] .
Elevated circulating levels of leptin are related with arterial hypertension [78] [79] [80] . In an animal model of hyperleptinemia not associated with obesity, Beltowski et al. demonstrated that leptin increases systolic blood pressure. This effect was accompanied by an increase in systemic and intrarenal oxidative stress. This increase of ROS leads to inactivation of nitric oxide, which binds with superoxide to form peroxynitrite and decreases renal sodium excretion in the rat. These results may explain the development of hypertension associated with high leptin levels [81] .
As mentioned above, a major source of superoxide anion in the heart is the NADPH oxidase family. Recently, phagocytic NADPH oxidase overactivity has been shown to be associated with markers of subclinical atherosclerosis such as carotid intima-media thickness in asymptomatic patients free of overt clinical atherosclerotic disease [82] . Fortuno et al. have shown that superoxide anion production is increased in peripheral blood mononuclear cells (PBMCs) from obese patients. This fact is positively correlated with increases in plasma leptin levels observed in obese patients after adjusting for age and sex. This increment in superoxide anion is mediated via NADPH oxidase since the presence of apocynin, diphenylene (DPI), and SOD inhibited this production in PBMCs. In the same way, leptin increased superoxide anion production in PBMCs from healthy individuals, and the superoxide anion production induced by leptin was higher in PBMCs from the obese group than in those from the control one and inhibited by apocynin and DPI. These effects were accompanied by a translocation of p47phox subunit from cytosol to membrane fraction through the PI3K/protein kinase C (PKC) signaling pathway. Furthermore, leptin increased the proliferation of macrophages in a dose-dependent manner. These findings show that phagocytic NADPH oxidase activity is increased in obesity. This increase may be due to the hyperleptinemia that is found in obese population [75] .
In this way, stimulation of cultured human umbilical vein endothelial cells (HUVECs) with leptin leads to an enhanced intracellular accumulation of ROS in a time-and dose-dependent manner. In protein extracts obtained from these cells, leptin exhibited a time-dependent increase in JNK activity. The transcription factor AP-1 is a downstream target of JNK. Nuclear extracts from cells stimulated by leptin evoked a time-dependent appearance of two bands, reflecting an enhanced association of nuclear proteins with the AP-1 consensus sequence. The activity of the transcription factor NF-κB is sensitive to intracellular redox changes. Leptin increased the activity of NF-κB in an oxidant-dependent manner. All of these effects of leptin were reverted with pretreatment of cells with the antioxidant N-acetylcysteine (NAC). Therefore, leptin increases the accumulation of ROS in endothelial cells, which acts as signaling messengers capable of activating intracellular transduction pathways and transcriptions factors sensitive to changes in intracellular redox state [83] .
In human aortic smooth muscle cells (HASMCs), leptin induces proliferation and MMP-2 and ROS production in a dose-dependent manner through the activation of NAD(P)H oxidase since the presence of the NAD(P)H oxidase inhibitors, apocynin and DPI, reduces this increment in ROS, proliferation, and MMP-2 production . This study shows that oxidative stress generated by leptin could generate adverse effects observed in individuals with high cardiovascular risk [84] .
All of these data show that elevated circulating leptin levels, or an increase in the levels produced locally in the heart, could play an important role in cardiovascular disease partly by an increase in oxidative stress. Leptin itself, or the oxidative stress generated by leptin, produces a variety of deleterious effects, such as changes in cardiac metabolism, hypertrophic and fibrotic effects that generate functional and structural changes that can favor the cardiac alterations associated with obesity ( Figure 1 ).
Expert opinion
The relationship between obesity and increased risk for the development of cardiovascular disease is well known. Obesity produces distinct changes in myocardial biochemistry, structure, and function. Although a clear mechanistic basis for increased cardiovascular risk in obese individuals is uncertain, leptin has received some attention as a potential causative or at least a contributing factor for this phenomenon.
Several studies have demonstrated that leptin is able to regulate a variety of cardiac and vascular effects that include hypertensive [85] , atherosclerotic effects [86] , endothelial dysfunction [87] , and thrombosis induction [88] . At cardiac level, although some data are contradictory, leptin seem to contribute to the modulation of metabolism, hypertrophic effects, and turnover of ECM, so hyperleptinemia is independently related to poorer cardiovascular outcome.
Some studies consider leptin as an independent predictor for cardiovascular morbidity and mortality and have been identified as a risk factor for myocardial infarction [89] [90] [91] . However, a study involving the Quebec Cardiovascular Study population, which is restricted to male subjects, did not confirm those findings [92] . Leptin has also been linked to the occurrence of future stroke [93] [94] [95] , identified as an independent predictor stroke even after the adjustment for other traditional risk factors including CRP. 
Outlook
The use of leptin as a potential new biomarker is limited by its strong dependence on BMI and fat mass, particularly abdominal fat. The discussion of the predictive value of leptin in chronic heart failure is currently limited by the relative small number of studies and the lack of outcome trials analyzing the predictive value of leptin in those patients. Nevertheless, one might assume that the close correlation of leptin to several well-established markers of risk and clinical outcome in obese patients might qualify this hormone for further testing. A knowledge of the mechanism that leptin employs to mediate all of the cardiovascular effects may allow therapeutic exploitation of the cardioprotective effects of leptin while avoiding injurious outcomes.
Highlights
-Obesity is associated with structural and functional changes in the heart. -Leptin and its receptors are expressed in several tissues including myocardium and mediate a wide array of direct effects in the heart.
-Leptin alters cardiac metabolism by increasing FA utilization and oxidation. -Leptin confers cardioprotection via attenuation of cardiomyocyte apoptosis. -Leptin exerts hypertrophic effects through the activation of angiotensin II and endothelin-1 and by stimulating generation of ROS. -ECM can profoundly alter cardiac size, structure, and function in heart. Leptin is able to alter ECM synthesis and turnover. -Leptin could play an important role in cardiovascular disease by an increase, in part, in oxidative stress.
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